On Wednesday, October 11, 2023, we teamed up with Cyberport, HKMHDIA, and UMP Innov Centre to host the “Bright Ideas, Strong Barriers: A Patenting Masterclass” seminar, both in-person and online. Jennifer, our Managing Director, and Pauli, our Principal, took the stage and delivered presentations on the fundamentals of intellectual property (IP) and the challenges faced in MedTech/Healthcare innovation within the GBA and China.

We were privileged to have a distinguished panel of experts who generously shared their experiences and insights on the topic of “MedTech Innovations and Intellectual Property Protection.” Our esteemed panelists included Ronnie Li from UMP Healthcare Group as the moderator, Dr. Lydia Leung from HKMHDIA and Belun Technology, Mr. Justin Chan from Gense Technologies, Ms. Kim Chow from LinkAIQ, and our very own Managing Director, Ms. Jennifer Che.

At Eagle IP Limited, our mission is to assist both local and foreign inventors in safeguarding their creations and business endeavors. Through seminars like these, we aim to raise awareness about the importance of IP in the technology industry. We eagerly anticipate organizing more IP workshops and events for our community!






Our Past Events

Recommended Insights

Obviousness: can features from different categories of products be combined to invalidate a design patent?

18 September 2025
Introduction “I have a tank, I have a gun—boom! Tank gun?” Each year the CNIPA releases a list of Top Ten Patent Re-examination and Invalidation Cases. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Over the next several months we will be highlighting many […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

12 November 2018
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data

23 January 2026
On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026. Novo Nordisk announced this positive news via a press release on the day the case was decided. The Chinese Ministry of Commerce has also confirmed this decision […]

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
Top crossarrow-right